About Us
BD2 brings together researchers, clinicians, philanthropists, and people with lived experience to study and treat bipolar disorder in a new way.
For individuals living with bipolar disorder, their families, and the researchers and clinicians who care for them, BD2 is the transformational force unlocking scientific understanding that improves clinical outcomes and allows those with bipolar disorder to thrive.
Taking learnings from the development of Aligning Science Across Parkinson’s (ASAP), and working alongside scientists, clinicians, and people with lived experience, philanthropic investors united with the Milken Institute to establish BD2: Breakthrough Discoveries for thriving with Bipolar Disorder.
Through an integrated, collaborative approach, BD2 is addressing knowledge gaps in the basic disease mechanisms of bipolar disorder as well as factors influencing clinical approaches and outcomes. This initial $150 million effort provides an unprecedented opportunity to improve the lives of people with bipolar disorder and those yet to be diagnosed.
